Irsigler G B, Ker J
S Afr Med J. 1978 Apr 15;53(15):571-3.
A new beta 2-adrenergic bronchodilator, carbuterol, was compared with hexoprenaline and placebo, by double-blind crossover technique in 10 adult asthmatic patients. Carbuterol 200 microgram was compared with hexoprenaline 200 microgram, corresponding to 2 inhalations from a standard aerosol in each case. The carbuterol effect, in terms of vital capacity and forced expiratory volume in 1 second (FEV1) was significantly longer than that of hexoprenaline. Its effect on airways resistance also appeared to be longer, although this difference was not statistically significant. The difference in duration of action may be due to greater potency of carbuterol, or to a longer elimination half-life of carbuterol. No significant effects on heart rate or blood pressure were noted with either drug.
采用双盲交叉技术,在10名成年哮喘患者中,将一种新型β2-肾上腺素能支气管扩张剂卡布特罗与己双肾上腺素及安慰剂进行了比较。将200微克卡布特罗与200微克己双肾上腺素进行比较,每种情况均相当于从标准气雾剂吸入2次。就肺活量和一秒用力呼气量(FEV1)而言,卡布特罗的作用明显长于己双肾上腺素。其对气道阻力的作用似乎也更长,尽管这种差异无统计学意义。作用持续时间的差异可能是由于卡布特罗效力更强,或其消除半衰期更长。两种药物对心率或血压均无显著影响。